Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to determine whether treatment with tiotropium (18
mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD
experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation
during a six month observation period.